How does drostanolone enanthate bind to the androgen receptor compared to testosterone?

Drostanolone binds the androgen receptor with a relative binding affinity roughly 3.0–3.5 times higher than testosterone, as determined in competitive binding assays using methyltrienolone as the reference ligand. This elevated affinity results from the compound's DHT-based structure combined with the 2α-methyl group that prevents 3α-HSD-mediated inactivation, keeping the molecule receptor-active in muscle and other androgen-sensitive tissues longer than unmodified DHT.

What does drostanolone's DHT lineage mean for how it produces its androgenic effects?

Because drostanolone is a 2α-methylated derivative of dihydrotestosterone, all of its androgenic and anabolic activity is mediated directly through androgen receptor occupancy and subsequent transcriptional activation of androgen-response elements. It cannot be converted to oestrogen by aromatase, and it does not bind the progesterone receptor meaningfully — so every measurable effect, including nitrogen retention and myofibrillar protein synthesis upregulation, originates at the AR level.

Why does the 2α-methyl modification on drostanolone preserve androgenic activity in muscle tissue?

In muscle tissue, the enzyme 3α-hydroxysteroid dehydrogenase (3α-HSD) normally converts DHT to the inactive metabolite 3α-androstanediol, effectively limiting DHT's anabolic contribution. The 2α-methyl group on drostanolone creates steric hindrance that blocks this enzymatic reduction, allowing the parent compound to remain intact and receptor-bound at the intracellular level — a structural advantage that translates into sustained androgenic signalling compared to unmodified DHT.

How should Hilma Biocare Drostanolone Enanthate 200mg/ml be drawn and stored after the vial is first opened?

Use a standard 21–23 gauge needle for drawing from the 10ml multi-dose vial; an insulin syringe is not appropriate due to the oil-based carrier vehicle and the gauge required to aspirate it cleanly. After first puncture, store the vial upright at 15–25°C away from direct light; refrigeration is not required but is acceptable — allow the oil to reach room temperature before drawing to reduce viscosity. Discard any unused content showing particulate matter or cloudiness.

What is the recommended injection volume per administration from a 200mg/ml vial for someone using 400mg per week?

At a weekly dose of 400mg split across two injections, each administration requires 1.0ml drawn from the 200mg/ml vial. The 10ml vial contains 2,000mg total active compound at label concentration — verified by HPLC at the Hilma Biocare production stage — providing five full weeks of supply at this schedule. Always confirm vial integrity and label concentration prior to calculating volumes, particularly when transitioning from a different concentration product. (2) angle_used

Optimal Dosage

Hilma Biocare

Drostanolone Enanthate 200mg/ml 10ml Vial by Hilma Biocare

Name: Drostanolone Enanthate 200mg/ml 10ml Vial by Hilma Biocare
Brand: Hilma Biocare
SKU: INJ-DROE-HIL-200-006
Price: 48.00 EUR
Availability: InStock

Drostanolone Enanthate by Hilma Biocare is a dihydrotestosterone-derived injectable androgen formulated at 200mg/ml in a 10ml multi-dose vial, distinguished by its high androgen receptor binding affinity relative to testosterone and its structural inability to undergo aromatisation. The DHT backbone confers direct, receptor-mediated androgenic signalling without conversion to oestrogen, making receptor engagement — not metabolic redirection — the primary driver of its physiological effects. Quality verification for each batch is conducted through HPLC potency assay and LAL endotoxin screening, with results documented in a product-specific release dossier.

€48.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Direct androgen receptor activation without oestrogen conversion pathway involvement
Elevated AR binding affinity — approximately 3× testosterone — for efficient receptor occupancy
2α-methyl structural protection preserves compound activity against 3α-HSD enzymatic breakdown
Supports lean tissue nitrogen retention through androgen-response element transcription
200mg/ml concentration delivers meaningful per-injection dose in a compact 1ml volume
10ml multi-dose vial format suits extended administration schedules without frequent supply interruption
HPLC and LAL endotoxin testing at the batch level underpin dosing calculation accuracy

Phase	Dosage	Note
Introductory / Receptor-Sensitivity Assessment	200mg/week (1.0ml, split into two 0.5ml injections)	Establishes baseline AR response; allows monitoring of androgenic sensitivity before escalation
Intermediate / Sustained AR Engagement	400mg/week (2.0ml, split into two 1.0ml injections)	Optimal Dosing range for most users; sufficient receptor occupancy for measurable anabolic signal
Advanced / High AR Load	600mg/week (3.0ml, split into two 1.5ml injections)	Experienced users only; androgen-sensitive side effect monitoring essential at this receptor-load level
Female / Low-Dose Protocol	50–100mg/week (0.25–0.5ml, single weekly injection)	DHT-derived virilisation risk requires conservative AR engagement; not recommended for extended use

Key takeaways

Understand that drostanolone's AR affinity is analytically measured at 3–3.5× testosterone.
Recognise the 2α-methyl group as the structural key preventing 3α-HSD inactivation.
Confirm HPLC batch verification before calculating receptor-targeted dose volumes.
Choose enanthate ester scheduling to reduce injection frequency without sacrificing AR exposure.
Monitor androgen-sensitive markers to assess receptor-level response throughout the cycle.

Drostanolone Enanthate: Androgen Receptor Binding as the Core Mechanism

Drostanolone Enanthate is a 2α-methyl derivative of dihydrotestosterone esterified with enanthic acid, a structural configuration that delivers androgenic activity exclusively through direct androgen receptor (AR) occupancy rather than through the oestrogen receptor or progestogenic pathways. This mechanistic specificity sets it apart from testosterone and 19-nor compounds, which interact with multiple steroid receptor classes. The 2α-methyl substitution on the DHT scaffold is not cosmetic — it sterically hinders the enzyme 3α-hydroxysteroid dehydrogenase from reducing drostanolone to an inactive 3α-diol metabolite, preserving receptor-active compound in target tissues.

Androgen Receptor Affinity: Quantified and Contextualised

Drostanolone's relative binding affinity (RBA) for the androgen receptor has been measured at approximately 3.0–3.5 times that of testosterone in in-vitro competitive binding assays (reference ligand: methyltrienolone/R1881). This figure reflects the combined effect of DHT's inherent AR selectivity and the protection from 3α-reduction that the 2α-methyl group provides. Compared to unmodified DHT, which is rapidly inactivated in muscle tissue by 3α-HSD, drostanolone sustains meaningful receptor occupancy — meaning its androgenic signal is more durable at the tissue level despite a structurally similar parent nucleus.

Receptor Selectivity and the Absence of Aromatisation

Because drostanolone is derived from DHT rather than testosterone, it lacks the C19 configuration and A-ring structure that aromatase requires for oestrogen conversion. Hilma Biocare's Drostanolone Enanthate therefore does not contribute to circulating oestradiol load — a receptor-level fact with direct implications for water retention and oestrogen-driven feedback suppression. The androgen-receptor-mediated pathway handles all measurable anabolic and androgenic output: AR activation drives nitrogen retention, myofibrillar protein synthesis, and erythropoietic signalling through transcriptional upregulation of androgen-response elements (AREs).

Pharmacological Integrity: From Raw API to Final Vial

Hilma Biocare validates the receptor-relevant concentration of this product — the stated 200mg/ml — through HPLC analysis at the finished-product stage, cross-referenced against an incoming API potency certificate for the drostanolone enanthate raw material. LAL endotoxin testing is applied to the injectable solution prior to vial filling, establishing a pyrogen-control checkpoint that is specific to this formulation rather than shared across an oil-based injectable template. Every quantitative claim on the label corresponds to an analytically generated data point in the batch record.

Usage

Confirm the HPLC batch certificate for your specific Hilma Biocare Drostanolone Enanthate 200mg/ml vial to establish the verified concentration before calculating any receptor-targeting dose.
Calculate your weekly milligram target based on your AR engagement goal — divide total weekly dose by two to determine per-injection volume in millilitres from the 200mg/ml vial.
Draw using a 21-gauge needle into a 2–3ml syringe; allow the sesame or grape-seed oil carrier to reach room temperature (20–23°C) to ensure smooth aspiration and reduce injection-site discomfort.
Administer via intramuscular injection into the gluteal, lateral quadriceps, or deltoid site; rotate injection sites across both sides to prevent localised androgen-receptor overstimulation and tissue fibrosis.
Schedule injections on fixed weekdays (e.g. Monday and Thursday) to maintain consistent plasma-level support for steady AR occupancy throughout the active release window.
Log each injection volume, site, and date alongside any subjective androgen-response markers (libido, pump quality, vascularity); use this record to inform dose adjustments at the next assessment checkpoint.

Warnings

Contraindications: Drostanolone Enanthate is contraindicated in individuals with known or suspected androgen-sensitive prostate carcinoma or breast cancer in males. It must not be used in women who are pregnant or may become pregnant. Individuals with severe hepatic impairment, untreated hypercalcaemia, or diagnosed benign prostatic hyperplasia should avoid androgen receptor agonists of this potency class.

Side Effects: DHT-derived AR agonists carry an elevated risk of androgenic effects including accelerated scalp hair loss in genetically predisposed individuals, acne vulgaris at sebaceous-rich skin sites, and potential benign prostatic tissue stimulation with long-term use. Suppression of the hypothalamic-pituitary-gonadal (HPG) axis is expected; endogenous testosterone production is reduced in proportion to dose and duration. Lipid profile disruption — specifically HDL reduction and LDL elevation — has been documented in studies of androgen administration and should be anticipated.

Monitoring: Obtain a lipid panel (HDL, LDL, total cholesterol, triglycerides) and haematological profile at baseline and at 6–8 week intervals. PSA screening is appropriate for users over 35. Liver enzyme panels (ALT, AST) should be checked routinely even with injectable androgens, as systemic AR activation can influence hepatic lipid metabolism. Blood pressure monitoring is advisable throughout the cycle.

PCT: Following cessation of Drostanolone Enanthate, HPG axis recovery requires structured post-cycle therapy. Allow sufficient time for active compound clearance given the long enanthate ester release profile before initiating SERMs such as tamoxifen or clomiphene. A standard PCT window of 4–6 weeks with appropriate SERM dosing supports endogenous LH and FSH recovery and restoration of testicular steroidogenesis.

Frequently asked questions

How does drostanolone enanthate bind to the androgen receptor compared to testosterone?: Drostanolone binds the androgen receptor with a relative binding affinity roughly 3.0–3.5 times higher than testosterone, as determined in competitive binding assays using methyltrienolone as the reference ligand. This elevated affinity results from the compound's DHT-based structure combined with the 2α-methyl group that prevents 3α-HSD-mediated inactivation, keeping the molecule receptor-active in muscle and other androgen-sensitive tissues longer than unmodified DHT.
What does drostanolone's DHT lineage mean for how it produces its androgenic effects?: Because drostanolone is a 2α-methylated derivative of dihydrotestosterone, all of its androgenic and anabolic activity is mediated directly through androgen receptor occupancy and subsequent transcriptional activation of androgen-response elements. It cannot be converted to oestrogen by aromatase, and it does not bind the progesterone receptor meaningfully — so every measurable effect, including nitrogen retention and myofibrillar protein synthesis upregulation, originates at the AR level.
Why does the 2α-methyl modification on drostanolone preserve androgenic activity in muscle tissue?: In muscle tissue, the enzyme 3α-hydroxysteroid dehydrogenase (3α-HSD) normally converts DHT to the inactive metabolite 3α-androstanediol, effectively limiting DHT's anabolic contribution. The 2α-methyl group on drostanolone creates steric hindrance that blocks this enzymatic reduction, allowing the parent compound to remain intact and receptor-bound at the intracellular level — a structural advantage that translates into sustained androgenic signalling compared to unmodified DHT.
How should Hilma Biocare Drostanolone Enanthate 200mg/ml be drawn and stored after the vial is first opened?: Use a standard 21–23 gauge needle for drawing from the 10ml multi-dose vial; an insulin syringe is not appropriate due to the oil-based carrier vehicle and the gauge required to aspirate it cleanly. After first puncture, store the vial upright at 15–25°C away from direct light; refrigeration is not required but is acceptable — allow the oil to reach room temperature before drawing to reduce viscosity. Discard any unused content showing particulate matter or cloudiness.
What is the recommended injection volume per administration from a 200mg/ml vial for someone using 400mg per week?: At a weekly dose of 400mg split across two injections, each administration requires 1.0ml drawn from the 200mg/ml vial. The 10ml vial contains 2,000mg total active compound at label concentration — verified by HPLC at the Hilma Biocare production stage — providing five full weeks of supply at this schedule. Always confirm vial integrity and label concentration prior to calculating volumes, particularly when transitioning from a different concentration product. (2) angle_used

Manufacturer

Hilma Biocare's quality control architecture for its injectable anabolic range is built around a principle of formulation-specific analytical validation: for Drostanolone Enanthate 200mg/ml, the incoming drostanolone enanthate API undergoes potency assessment by HPLC before it is released into the compounding workflow, generating a concentration data point that is reconciled against the finished-product HPLC result after vial filling — establishing a two-checkpoint potency chain unique to this SKU rather than inferred from a shared oil-injectable template. LAL (Limulus Amebocyte Lysate) endotoxin testing is applied at the solution stage prior to vial filling; the resulting endotoxin count is recorded in the batch-specific release dossier alongside the HPLC potency figures, meaning the 200mg/ml label claim is supported by documented analytical evidence rather than nominal assumption. Vial filling and stopper sealing occur under GMP-compliant aseptic conditions with environmental particulate and microbial monitoring maintained at ISO-classified cleanroom standards — conditions that are applied to this formulation as a discrete production event, not as a generalised injectable line run.

Product details

Brand	Hilma Biocare
Active ingredient	drostanolone enanthate
Also known as	Masteron Enanthate, Drostanolone Enanthat, Drostanolonee Enanthate, Hilma Biocare Masteron Enanthate
Strength	200 mg
Form	Vial
Pack size	1 piece
Item number	INJ-DROE-HIL-200-006

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

High Concentration

Etho-Masteron 200mg/ml 10ml Vial by Beligas Pharmaceuticals

Etho-Masteron by Beligas Pharmaceuticals is a high-concentration injectable Drostanolone Enanthate solution, dosed at 200mg/ml in a 10ml vial, engineered to integrate cleanly into structured, periodized cycle protocols where sustained androgenic support is the primary objective. The extended-release enanthate ester makes it particularly well-suited to modern cutting and recomposition blueprints that demand stable hormone levels over multi-week blocks without frequent injection windows. Batch release is governed by HPLC chromatographic quantification against certified reference standards; sterility is confirmed via LAL endotoxin assay — both conducted under GMP-compliant production conditions at Beligas Pharmaceuticals.

€54.00

Masten-200 200mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Masten-200 200mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Masten-200 is a long-chain ester injectable delivering Drostanolone Enanthate at 200 mg/ml across ten single-dose glass ampoules, distinguished by its extended pharmacokinetic profile — a half-life of approximately 10–11 days that enables stable plasma concentrations between infrequent administrations. The enanthate ester slows enzymatic cleavage of the parent hormone, sustaining active Drostanolone release across a broad time window rather than producing the sharp peak-and-trough pattern of shorter ester variants. Each batch undergoes HPLC-verified potency confirmation and LAL endotoxin testing; sterile fill integrity is independently validated before release by BM Pharmaceuticals.

€55.00

Brand Quality

Masteron 200 200mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Masteron 200 is an oil-based injectable delivering Drostanolone Enanthate at 200 mg/ml in a 10 ml vial, formulated specifically to support structured cruise-and-blast programming where androgenic density must shift between maintenance and growth phases without changing compounds. The long-acting enanthate ester sustains active hormone levels across the full blast window and remains pharmacokinetically compatible during reduced-dose cruise intervals. Each production batch of Masteron 200 is manufactured inside a GMP-certified facility; finished vials are HPLC-quantified against a certified Drostanolone reference standard and LAL-tested for endotoxin clearance before batch release.

€48.00

Pro Choice

Drostargos 200mg/ml 10ml Vial by Driada Medical

Drostargos is a long-acting injectable androgen from Driada Medical, delivering 200 mg of Drostanolone Enanthate per millilitre across a 10 ml multi-dose vial — formulated specifically to serve men over 40 pursuing hormone optimisation and anti-aging body-composition goals alongside or adjacent to testosterone replacement therapy. Its extended-release enanthate ester sustains stable androgenic activity across the week, making twice-weekly administration practical without sharp hormonal fluctuations that complicate quality-of-life management in older users. HPLC quantification of the active content and LAL endotoxin screening are completed at GMP Standard batch release; the resulting analytical certificate travels with each vial lot.

€56.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00